Compare SIGA & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SIGA | IMRX |
|---|---|---|
| Founded | 1995 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 309.8M | 265.3M |
| IPO Year | 2016 | 2021 |
| Metric | SIGA | IMRX |
|---|---|---|
| Price | $4.33 | $4.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $17.20 |
| AVG Volume (30 Days) | 348.2K | ★ 2.0M |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | ★ 13.24% | N/A |
| EPS Growth | N/A | ★ 37.75 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $224.81 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.10 | $2.90 |
| 52 Week High | $9.62 | $10.08 |
| Indicator | SIGA | IMRX |
|---|---|---|
| Relative Strength Index (RSI) | 43.37 | 48.71 |
| Support Level | $4.26 | $4.49 |
| Resistance Level | $4.80 | $5.27 |
| Average True Range (ATR) | 0.09 | 0.27 |
| MACD | 0.01 | 0.07 |
| Stochastic Oscillator | 35.00 | 81.33 |
SIGA Technologies Inc a commercial-stage pharmaceutical company. The Company sells its product, TPOX oral TPOXX, also known as tecovirimat, Tecovirimat-SIGA, or TEPOXX (tecovirimat) in certain international markets, to the U.S. Government and international governments (including government-affiliated entities). The Company operates in one single operating and reportable segment, which includes all activities related to the sale of the Company's Oral and IV TPOXX as well as research and development services.
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.